InterCure (NASDAQ:INCR) Trading Up 9.4% – Still a Buy?

InterCure Ltd. (NASDAQ:INCR) shares rose 9.4% during trading on Monday . The company traded as high as $0.9556 and last traded at $0.9560. Approximately 73,559 shares were traded during trading, an increase of 24% from the average daily volume of 59,395 shares. The stock had previously closed at $0.8740.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of InterCure in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

InterCure Stock Up 9.4%

The business’s fifty day simple moving average is $0.87 and its 200 day simple moving average is $0.94. The company has a current ratio of 1.48, a quick ratio of 0.97 and a debt-to-equity ratio of 0.20. The stock has a market cap of $52.27 million, a price-to-earnings ratio of 31.87 and a beta of 1.38.

InterCure (NASDAQ:INCR) last released its earnings results on Thursday, April 30th. The company reported ($0.10) EPS for the quarter. The business had revenue of $23.15 million for the quarter.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.